Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
A Two-part, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of SENS-401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Sponsor: Sensorion
Listed as NCT03603314, this PHASE2/PHASE3 trial focuses on Severe Sudden Sensorineural Hearing Loss and remains completed. Sponsored by Sensorion, it has been updated 10 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2/PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Feb 2022 — Apr 2023 [monthly]
Completed PHASE2_PHASE3
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Jan 2021 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2020 — Nov 2020 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2018 — Jun 2020 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sensorion
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Belgrade, Serbia , Brno, Czechia , Burgas, Bulgaria , Clamart, France , Hadera, Israel , Haifa, Israel , Hradec Králové, Czechia , Istanbul, Turkey (Türkiye) , Liptovský Mikuláš, Slovakia , Marseille, France and 14 more locations